Proven Connect Logo
New investment into Nanovery
Thanks to Proven Connects investor partnership with UKRI we were able to be the lead the latest investment round Nanovery
Article Information
Date: December 22, 2022

Share this

Thanks to Proven Connects investor partnership with UKRI we were able to be the lead the latest investment round Nanovery. Nanovery have successfully completed funding raise including co-investment from the Northstar Ventures. The £1.85m raise included £750K non-diluted grant funding from Innovatge UK. This funding not only accelerates the company’s progress it also helps to de-risk investments and encourage greater private investment.

Nanovery are developing a technology that will results in patients having a blood test that will provide:

  • An earlier and more accurate diagnosis  of prostate cancer reducing the need for unnecessary biopsies
  • Support the development and deployment of precision medicine and enable clinicians to better predict the right treatment for the right patient at the right time
  • Enable better monitoring of disease progression and so reassure patients who are placed on active surveillance

If successful Nanovery’s technology hopes to not only remove the uncertainty around a prostate cancer diagnosis, in terms of the aggressive nature of a man’s disease. It will also reduce over treatment with the sometimes debilitating and life changing side effects.

Nanovery secures over £1.85 million for cancer diagnostic solution - Prostate Cancer Research (prostate-cancer-research.org.uk)

 

“I was diagnosed with cancer and after treatment (which was quite difficult) I didn't realise how many questions or experiences I wished I had known about. “(Ray)

If successful Nanovery’s technology will enable men like Ray to receive a diagnosis which tells them how aggressive their cancer is likely to be and recommend the best course of treatment.